A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

NCT01300858 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Sites could not enroll patients.

Conditions

Colorectal Cancer

Interventions

DRUG: EGEN-001-301

Sponsor

EGEN, Inc.